Bioinformatics Analysis of ZBTB16 As a Prognostic Marker for Ewing's Sarcoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2021 Oct 18

PMID 34660783

Citations 2

Authors

Ke Ding

Wenli Qiu

Dianbo Yu

Huade Ma

Kangqi Xie

Fuqiang Luo

Shanlang Li

Zaiyong Li

Jihua Wei

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study is to identify novel biomarkers for the prognosis of Ewing's sarcoma based on bioinformatics analysis.

Methods: The GSE63157 and GSE17679 datasets contain patient and healthy control microarray data that were downloaded from the Gene Expression Omnibus (GEO) database and analyzed through R language software to obtain differentially expressed genes (DEGs). Firstly, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment, protein-protein interaction (PPI) networks, and Cytoscape Molecular Complex Detection (MCODE) plug-in were then used to compute the highest scores of the module. After survival analysis, the hub genes were lastly obtained from the two module genes.

Results: A total of 1181 DEGs were identified from the two GSEs. Through MCODE and survival analysis, we obtain 53 DEGs from the module and 29 overall survival- (OS-) related genes. ZBTB16 was the only downregulated gene after Venn diagrams. Survival analysis indicates that there was a significant correlation between the high expression of ZBTB16 and the OS of Ewing's sarcoma (ES), and the low expression group had an unfavorable OS when compared to the high expression group.

Conclusions: High expression of ZBTB16 may serve as a predictor biomarker of poor prognosis in ES patients.

Citing Articles

Integrative analyses of bulk microarray data to discover genes, pathways, and immune infiltration characteristics associated with targeting of Ewing sarcoma.

Cao B, Sun H, Fan Z, Khawar M, Cai L, Yu S J Cancer Res Clin Oncol. 2023; 149(10):6967-6977.

PMID: 36849756 PMC: 10374716. DOI: 10.1007/s00432-023-04642-0.

COL8A1 Predicts the Clinical Prognosis of Gastric Cancer and Is Related to Epithelial-Mesenchymal Transition.

She Y, Zhao X, Wu P, Xue L, Wan S, Zhang L Biomed Res Int. 2022; 2022:7567447.

PMID: 35774273 PMC: 9239809. DOI: 10.1155/2022/7567447.

References

Rodl R, Hoffmann C, Gosheger G, Leidinger B, Jurgens H, Winkelmann W . Ewing's sarcoma of the pelvis: combined surgery and radiotherapy treatment. J Surg Oncol. 2003; 83(3):154-60. DOI: 10.1002/jso.10256. View

Chin M, Yokoyama R, Sumi M, Okita H, Kawai A, Hosono A . Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04. Pediatr Blood Cancer. 2020; 67(5):e28194. DOI: 10.1002/pbc.28194. View

Jiang F, Wang Z . Identification and characterization of PLZF as a prostatic androgen-responsive gene. Prostate. 2004; 59(4):426-35. DOI: 10.1002/pros.20000. View

Albergo J, Gaston C, Parry M, Laitinen M, Jeys L, Tillman R . Risk analysis factors for local recurrence in Ewing's sarcoma: when should adjuvant radiotherapy be administered?. Bone Joint J. 2018; 100-B(2):247-255. DOI: 10.1302/0301-620X.100B2.BJJ-2017-0222.R1. View

Marofi F, Vahedi G, Solali S, Alivand M, Salarinasab S, Zadi Heydarabad M . Gene expression of TWIST1 and ZBTB16 is regulated by methylation modifications during the osteoblastic differentiation of mesenchymal stem cells. J Cell Physiol. 2018; 234(5):6230-6243. DOI: 10.1002/jcp.27352. View

Oesterheld J, Reed D, Setty B, Isakoff M, Thompson P, Yin H . Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatr Blood Cancer. 2020; 67(7):e28370. PMC: 7771264. DOI: 10.1002/pbc.28370. View

Chen Z, Brand N, Chen A, Chen S, Tong J, Wang Z . Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 1993; 12(3):1161-7. PMC: 413318. DOI: 10.1002/j.1460-2075.1993.tb05757.x. View

Plaisier C, Bennett B, He A, Guan B, Lusis A, Reue K . Zbtb16 has a role in brown adipocyte bioenergetics. Nutr Diabetes. 2013; 2:e46. PMC: 3461357. DOI: 10.1038/nutd.2012.21. View

He J, Wu M, Xiong L, Gong Y, Yu R, Peng W . BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27. Clin Epigenetics. 2020; 12(1):82. PMC: 7285556. DOI: 10.1186/s13148-020-00867-9. View

10.

Alvarez-SanNicolas J, Gracia-Alegria I, Trullols-Tarrago L, Peiro-Ibanez A, Lamas-Gomez C . Prognostic factors and survival in Ewing's sarcoma treated by limb salvage surgery. Clin Transl Oncol. 2019; 21(10):1374-1382. DOI: 10.1007/s12094-019-02067-1. View

11.

Pretz J, Barysauskas C, George S, Hornick J, Raut C, Chen Y . Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. Oncologist. 2017; 22(10):1265-1270. PMC: 5634761. DOI: 10.1634/theoncologist.2016-0463. View

12.

Jamshidi K, Ramezan Shirazi M, Bagherifard A, Mirzaei A . Curettage, phenolization, and cementation in paediatric Ewing's sarcoma with a complete radiological response to neoadjuvant chemotherapy. Int Orthop. 2018; 43(2):467-473. DOI: 10.1007/s00264-018-4094-5. View

13.

Orr W, Denbo J, Billups C, Wu J, Navid F, Rao B . Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol. 2012; 19(12):3816-22. DOI: 10.1245/s10434-012-2458-4. View

14.

Sbaraglia M, Righi A, Gambarotti M, Dei Tos A . Ewing sarcoma and Ewing-like tumors. Virchows Arch. 2019; 476(1):109-119. DOI: 10.1007/s00428-019-02720-8. View

15.

Farrell E, Armstrong A, Grimes A, Naya F, de Lange W, Ralphe J . Transcriptome Analysis of Cardiac Hypertrophic Growth in -Null Mice Suggests Early Responders in Hypertrophic Remodeling. Front Physiol. 2018; 9:1442. PMC: 6210548. DOI: 10.3389/fphys.2018.01442. View

16.

Hsieh C, Botta G, Gao S, Li T, Van Allen E, Treacy D . PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015; 75(10):1944-8. PMC: 4433564. DOI: 10.1158/0008-5472.CAN-14-3602. View

17.

Le Deley M, Delattre O, Schaefer K, Burchill S, Koehler G, Hogendoorn P . Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010; 28(12):1982-8. DOI: 10.1200/JCO.2009.23.3585. View

18.

Mendoza-Naranjo A, El-Naggar A, Wai D, Mistry P, Lazic N, Rojas Ayala F . ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013; 5(7):1087-102. PMC: 3721475. DOI: 10.1002/emmm.201202343. View

19.

Jawad M, Cheung M, Min E, Schneiderbauer M, Koniaris L, Scully S . Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer. 2009; 115(15):3526-36. DOI: 10.1002/cncr.24388. View

20.

Ambele M, Dessels C, Durandt C, Pepper M . Genome-wide analysis of gene expression during adipogenesis in human adipose-derived stromal cells reveals novel patterns of gene expression during adipocyte differentiation. Stem Cell Res. 2016; 16(3):725-34. DOI: 10.1016/j.scr.2016.04.011. View